CA14 | Carbonic anhydrase XIV | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
CA3 | Carbonic anhydrase III, muscle specific | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CA7 | Carbonic anhydrase VII | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Group enriched |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1B | Calcium channel, voltage-dependent, N type, alpha 1B subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Group enriched |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1D | Calcium channel, voltage-dependent, L type, alpha 1D subunit | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1G | Calcium channel, voltage-dependent, T type, alpha 1G subunit | FDA approved drug targets Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1H | Calcium channel, voltage-dependent, T type, alpha 1H subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CACNA1S | Calcium channel, voltage-dependent, L type, alpha 1S subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
CACNA2D1 | Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Mixed |
CACNA2D2 | Calcium channel, voltage-dependent, alpha 2/delta subunit 2 | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Tissue enriched |
CACNB1 | Calcium channel, voltage-dependent, beta 1 subunit | FDA approved drug targets Predicted intracellular proteins
| | | | | Group enriched |
CACNB2 | Calcium channel, voltage-dependent, beta 2 subunit | Disease related genes FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Mixed |
CACNB3 | Calcium channel, voltage-dependent, beta 3 subunit | FDA approved drug targets Predicted intracellular proteins Transporters
| | | | | Mixed |
CACNB4 | Calcium channel, voltage-dependent, beta 4 subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Transporters
| | | | | Tissue enhanced |
CALY | Calcyon neuron-specific vesicular protein | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CAMLG | Calcium modulating ligand | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
CARTPT | CART prepropeptide | FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CAT | Catalase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CCKAR | Cholecystokinin A receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CCKBR | Cholecystokinin B receptor | Cancer-related genes FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CCL2 | Chemokine (C-C motif) ligand 2 | Cancer-related genes Candidate cardiovascular disease genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
CCND1 | Cyclin D1 | Cancer-related genes Disease related genes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CD44 | CD44 molecule (Indian blood group) | Blood group antigen proteins Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Expressed in all |
CFTR | Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHD1 | Chromodomain helicase DNA binding protein 1 | Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Expressed in all |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CHRM2 | Cholinergic receptor, muscarinic 2 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CHRM3 | Cholinergic receptor, muscarinic 3 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
CHRM4 | Cholinergic receptor, muscarinic 4 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CHRM5 | Cholinergic receptor, muscarinic 5 | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
CHRNA3 | Cholinergic receptor, nicotinic, alpha 3 (neuronal) | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
CHRNA4 | Cholinergic receptor, nicotinic, alpha 4 (neuronal) | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CHRNA7 | Cholinergic receptor, nicotinic, alpha 7 (neuronal) | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
CKB | Creatine kinase, brain | Cancer-related genes Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Expressed in all |
CKM | Creatine kinase, muscle | Candidate cardiovascular disease genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CKMT1A | Creatine kinase, mitochondrial 1A | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Mixed |
CKMT1B | Creatine kinase, mitochondrial 1B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CKMT2 | Creatine kinase, mitochondrial 2 (sarcomeric) | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CLCN2 | Chloride channel, voltage-sensitive 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
CNR1 | Cannabinoid receptor 1 (brain) | FDA approved drug targets G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CNR2 | Cannabinoid receptor 2 (macrophage) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
COMT | Catechol-O-methyltransferase | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
CPS1 | Carbamoyl-phosphate synthase 1, mitochondrial | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |